{'fraction_non_alphanumeric': 0.027177700348432057, 'fraction_numerical': 0.027874564459930314, 'mean_word_length': 5.163090128755365, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Increased glucose tolerance in Type II Diabetics treated with a citrus extract: A pilot study

Diabetinol™, a dietary supplement, was tested in a placebo controlled clinical trial for its ability to improve the glucose tolerance of subjects when presented with a standard oral glucose challenge. Subjects were males and females between the ages of 18 and 75 with fasting glucose levels between 109.8mg/dl and 162mg/dl. Twenty subjects were randomly assigned to 2 treatment groups and received either Diabetinol™ (2x525mg/day) or a placebo (2x525mg/day) for 84 days. Control data was collected on day 0 and was compared against experimental data collected on days 28, 56 and 84 of the study. A significant (p<0.01) 19% reduction in glucose intolerance was observed in the Diabetinol™ treatment group after 84 days while no significant changes were observed in the placebo group. No statistically significant changes to the fasting plasma glucose or hemoglobin A1c (HbA1c) levels of either group were observed during this study; however, a downward trend was seen in the HbA1c levels of Diabetinol™‐treated subjects. These results suggest that when administered over a longer treatment period, Diabetinol™ significantly reduces glucose intolerance in individuals with Type II Diabetes. Additional studies on the efficacy of Diabetinol™ in Type II Diabetics will be conducted in a larger sample population over a 6‐month treatment period.